Salbutamol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using superpowers:using-superpowers — checked for relevant skills; this is a template-driven report-writing task fully specified by the prompt, no domain skill applies, so proceeding directly.
Salbutamol: From Asthma/COPD Bronchodilation to Papillary Conjunctivitis
One-Sentence Summary
Salbutamol is a short-acting β2-adrenergic receptor agonist (SABA) bronchodilator, established as a mainstay therapy for asthma and COPD-related bronchospasm. The TxGNN model's top-ranked prediction for this drug is Papillary Conjunctivitis, but currently 0 clinical trials and 0 publications directly support this specific indication — the prediction rests on model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma / COPD (bronchodilator) — no NZ Medsafe license record found; drug is currently not marketed in New Zealand |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.9964% |
| Evidence Level | L5 |
| New Zealand Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for salbutamol is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on generally known pharmacology, salbutamol is a selective β2-adrenoceptor agonist that relaxes bronchial smooth muscle; its efficacy in reversible airway obstruction (asthma, COPD, bronchospasm) is well established, and this is the mechanistic basis for essentially all of its approved and near-approved uses.
Papillary conjunctivitis, however, is an ocular surface condition, not an airway disease — the connective tissue between original indication and this predicted indication is not direct. The evidence pack itself acknowledges this: the repurposing rationale for this candidate states there is no clinical trial or literature support, and the mechanistic link is only an indirect analogy to allergic conjunctivitis pathophysiology.
That analogy has some basis elsewhere in this same evidence pack: for the separately-ranked candidate "atopic conjunctivitis" (rank 8), preclinical literature shows topically applied salbutamol suppressed immediate allergic conjunctivitis in an animal model (PMID 3666475) and that β2-agonists exert topical anti-inflammatory activity on conjunctival tissue (PMID 2906082). These findings are for allergic/atopic conjunctivitis, not papillary conjunctivitis specifically, and remain preclinical (animal/in vitro) — they should be read as a plausibility signal for the broader mechanistic class, not as direct evidence for this candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Salbutamol currently has no marketing authorization on record in New Zealand (0 licenses; market status: 未上市 / Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is the TxGNN model's highest-scoring predicted indication for salbutamol, but it has zero supporting clinical trials or literature, and the mechanistic connection to the original bronchodilator indication is only an indirect analogy — this places it at evidence level L5 (model prediction only).
To proceed, the following is needed:
- TFDA/Medsafe package insert data (warnings, contraindications — currently a Blocking data gap, DG001)
- Confirmed drug mechanism of action (DG002)
- Preclinical or clinical evidence specific to papillary conjunctivitis (current supporting literature only covers atopic/allergic conjunctivitis and is preclinical)
- If pursued, an initial pharmacology/mechanism study bridging β2-agonist activity to papillary conjunctivitis pathophysiology before considering any clinical investigation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.